Senior Manager/Associate Director Medical Affairs & Scientific Engagement
Avalo Therapeutics
Senior Manager/Associate Director Medical Affairs & Scientific Engagement
Avalo Therapeutics
Develops IL-1beta-targeting biologics for inflammation
At Avalo (ahh-vah'-low), we are 100% focused on developing treatments for immune-mediated inflammatory diseases with large unmet needs that affect millions worldwide. Our strategy is to develop medicines that target the IL-1β pathway, which is a central driver of the inflammatory process.
We share a commitment to teamwork, passion for science, and dedication to patients suffering from acute and chronic inflammatory disorders. Our collective expertise in discovery, development, and regulatory approvals is evidenced in our strong individual track records of advancing multiple therapeutic programs to successful commercialization.
Position Summary:
In collaboration with the VP, Medical Affairs, the Sr. Manager/Associate Director Medical Affairs & Scientific Engagement will play a key role in the development and execution of Avalo Therapeutics’ Medical Affairs strategy, with a particular focus on scientific communications, publication planning, congress strategy, medical education, external scientific engagement, and support of Avalo’s clinical development program in Hidradenitis Suppurativa (HS).
This individual will partner closely with Medical Affairs, Clinical Development, and Clinical Operations to translate emerging clinical and scientific data into meaningful scientific communications and educational initiatives for healthcare professionals, investigators, clinical study sites, and other external stakeholders.
A core component of the position will involve traditional Medical Affairs activities, including publication strategy, congress planning and execution, scientific communications, medical education, KOL engagement, advisory boards, and development of disease-state and scientific materials. The individual will help ensure that Avalo’s scientific evidence and emerging clinical data are communicated accurately, consistently, and effectively across appropriate external scientific channels.
The role will also provide scientific support to Avalo’s clinical development program by educating investigators and clinical study sites on HS disease state, the scientific rationale for the program, the target patient profile, and factors affecting patient identification, recruitment, enrollment, and retention. The individual will serve as a scientific bridge between Medical Affairs, Clinical Development, Clinical Operations, investigators, and study sites, helping translate field and site insights into actionable recommendations that support both Medical Affairs strategy and successful clinical study execution.
Essential Duties and Responsibilities:
Medical Affairs Strategy, Scientific Communications & Education
Publication Strategy & Scientific Evidence Dissemination
Congress & Conference Strategy
Medical Education & External Scientific Engagement
Clinical Study & Investigator/Site Scientific Support
Cross-Functional Collaboration
Required Education and Experience:
• An advanced scientific or clinical degree in a relevant discipline, such as an MD, DO, DNP, NP or PA in Dermatology or Rheumatology.
• 5+ years of relevant experience in clinical dermatology practice, or rheumatology, biotechnology, pharmaceuticals, Medical Affairs, Clinical Development, or related scientific roles.
• Experience in Medical Affairs, field medical/MSL, clinical trial liaison, or a clinician in dermatology or rheumatology.
• Preferred Demonstrated experience supporting publication planning, scientific communications, medical congresses, medical education, advisory boards, or related Medical Affairs activities.
• Demonstrated ability to interpret and communicate complex scientific and clinical data to internal and external audiences.
• Experience building relationships with KOLs, investigators, healthcare professionals, or academic researchers.
• Strong organizational and project-management skills, with the ability to manage multiple priorities and work independently across functional boundaries.
• Excellent written, verbal, presentation, and interpersonal communication skills.
• Ability to travel approximately 30–50% based on field, study, and congress needs.
Preferred Qualifications
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1–4% of the population globally. Avalo is pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb. For more information about Avalo, please visit www.avalotx.com.
ATTENTION: External Agencies and Placement Firms
A member of the Avalo Human Resources Department will contact an agency directly if an open position is eligible to be sourced from an outside recruiting service. Avalo does not accept unsolicited resumes from employment agencies for any employment opportunity. All agencies/recruiters must have a written agreement/SOW in place with Avalo and prior to submitting any resume or CV.
All resumes must be submitted through the appropriate process. Any resumes submitted without an agreement and/or any resumes sent unsolicited through e-mail accounts of Avalo employees will be considered outside of the appropriate process, do not imply or create any obligation on our part, do not impart any restrictions on Avalo with respect to the hiring of any persons whose resumes are so submitted and are not eligible for placement fees.
Develops IL-1beta-targeting biologics for inflammation
Avalo Therapeutics develops biologic therapies that target the IL-1beta pathway for immune-mediated inflammatory diseases. Its lead candidate, abdakibart (AVTX-009), is a humanized monoclonal antibody that inhibits IL-1beta and blocks downstream inflammatory signaling, advancing toward a registrational Phase 3 program after positive Phase 2 results in hidradenitis suppurativa. AVTX-010 is a long-acting next-generation anti-IL-1beta antibody designed to extend dosing intervals. The company focuses on research and development of novel biologics with commercialization expected through pharmaceutical partnerships and product sales. Unlike some competitors that pursue broader or different inflammatory targets, Avalo concentrates specifically on IL-1beta–related inflammation with a pipeline aimed at improving dosing convenience and clinical outcomes in inflammatory diseases.
Explore more opportunities at Avalo Therapeutics